Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 18/20 | 0.49 |
| ▸ | DPP7 | Q9UHL4 | 14/20 | 0.49 |
| ▸ | DPP9 | Q86TI2 | 12/20 | 0.49 |
| ▸ | DPP8 | Q6V1X1 | 8/20 | 0.49 |
| ▸ | PSEN1 | P49768 | 1/20 | 0.41 |
| ▸ | PSEN2 | P49810 | 1/20 | 0.41 |
| ▸ | APH1B | Q8WW43 | 1/20 | 0.41 |
| ▸ | NCSTN | Q92542 | 1/20 | 0.41 |
| ▸ | APH1A | Q96BI3 | 1/20 | 0.41 |
| ▸ | PSENEN | Q9NZ42 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL441143 | 1.00 | DPP4 (0.49) | DPP4DPP7DPP9DPP8PSEN1 | |
| SCHEMBL438621 | 0.86 | DPP4 (0.37) | DPP4DPP7DPP9DPP8 | |
| SCHEMBL453474 | 0.86 | DPP4 (0.37) | DPP4DPP7DPP9DPP8 | |
| SCHEMBL5682058 | 0.81 | LMNA (0.42) | — | |
| SCHEMBL28572268 | 0.77 | TRPA1 (0.44) | — | |
| SCHEMBL3122351 | 0.75 | DPP4 (0.52) | DPP4DPP7DPP9DPP8 | |
| SCHEMBL3126529 | 0.75 | DPP4 (0.52) | DPP4DPP7DPP9DPP8 | |
| SCHEMBL8250509 | 0.74 | DPP4 (0.50) | DPP4DPP7DPP9DPP8PSEN1 | |
| SCHEMBL4861107 | 0.73 | HTT (0.44) | — | |
| SCHEMBL441587 | 0.72 | ALDH1A1 (0.34) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9273055-B2 | Tyrosine kinase inhibitors | CHEMBRIDGE CORPORATION (US) | 2016-03-01 | — | — | US | disclosed |
| US-20150038536-A1 | TYROSINE KINASE INHIBITORS | CHEMBRIDGE COPRPORATION | 2015-02-05 | — | — | US | disclosed |
| US-8822500-B2 | Tyrosine kinase inhibitors | CHEMBRIDGE CORPORATION (US) | 2014-09-02 | — | — | US | disclosed |
| US-20120065233-A1 | TYROSINE KINASE INHIBITORS | GREGOR VLAD EDWARD (US) | 2012-03-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150038536-A1 | TYROSINE KINASE INHIBITORS | ALK, ROS1, ABL1 | DPP4 2274/4885DPP7 1205/4885DPP9 1283/4885 |
| US-20120065233-A1 | TYROSINE KINASE INHIBITORS | ALK, ROS1, ABL1 | DPP4 2274/4885DPP7 1205/4885DPP9 1283/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.